title: Identification of the myotoxic site of the Lys49 phospholipase A(2) from Agkistrodon piscivorus piscivorus snake venom: synthetic C-terminal peptides from Lys49, but not from Asp49 myotoxins, exert membrane-damaging activities.
abstract: Group II phospholipase A(2) (PLA(2)) myotoxins found in the venoms of Crotalidae snakes can be divided into 'Asp49' and 'Lys49' isoforms, the latter being considered catalytically-inactive variants. Previous studies on one Lys49 isoform, myotoxin II from Bothrops asper, indicated that its myotoxic activity is due to the presence of a short cationic/hydrophobic sequence (115-129) near its C-terminus, which displays membrane-damaging properties. Since the C-terminal region of different group II PLA(2) myotoxins presents considerable sequence variability, synthetic peptides homologous to region 115-129 of myotoxin II, but corresponding to B. asper myotoxin III (Asp49), Agkistrodon piscivorus piscivorus Asp49 PLA(2) and Lys49 PLA(2), were studied to determine the possible functional relevance of such region for the toxic activities of these proteins. Results showed that both Lys49-derived peptides (p-BaK49 and p-AppK49) were able to lyse skeletal muscle C2C12 cells in culture, and to induce edema in the mouse footpad assay. Moreover, p-AppK49, which showed a markedly stronger cytotoxic potency than p-BaK49, additionally induced skeletal muscle necrosis when injected into mice. These observations unequivocally identify the sequence 115-129 (KKYKAYFKLKCKK) of the Lys49 PLA(2) of A. p. piscivorus as containing the key structural determinants needed for myotoxicity, and represent the first report of an unmodified, PLA(2)-derived short synthetic peptide with the ability to reproduce this effect of a parent toxin in vivo. On the other hand, the two Asp49-derived peptides did not show any toxic effects in vitro or in vivo, even at high concentrations. These findings suggests that Lys49 and Asp49 group II PLA(2)s might exert their myotoxic actions through different molecular mechanisms, by implying that the latter may not utilize their C-terminal regions as main membrane-destabilizing elements.
authors.affiliation: Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San José, Costa Rica.
authors.forename: C E
authors.initials: CE
authors.lastname: Núñez
authors.forename: Y
authors.initials: Y
authors.lastname: Angulo
authors.forename: B
authors.initials: B
authors.lastname: Lomonte
mesh_terms: D017836:Agkistrodon / Q000378:metabolism; D000595:Amino Acid Sequence; D000818:Animals; D000925:Anticoagulants / Q000494:pharmacology; D001216:Asparagine / Q000737:chemistry; D017837:Bothrops / Q000378:metabolism; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects*; D002478:Cells, Cultured; D003402:Creatine Kinase / Q000097:blood; D003435:Crotalid Venoms / Q000737:chemistry; D004487:Edema / Q000139:chemically induced; D006493:Heparin / Q000494:pharmacology*; D007273:Injections, Intramuscular; D007279:Injections, Subcutaneous; D007770:L-Lactate Dehydrogenase / Q000187:drug effects / Q000378:metabolism*; D008239:Lysine / Q000737:chemistry; D008566:Membranes / Q000187:drug effects; D051379:Mice; D018482:Muscle, Skeletal / Q000187:drug effects / Q000473:pathology*; D009336:Necrosis; D010741:Phospholipases A / Q000737:chemistry* / Q000633:toxicity; D011485:Protein Binding; D020033:Protein Isoforms / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D013329:Structure-Activity Relationship
chemical_list: D000925:Anticoagulants; D003435:Crotalid Venoms; D020033:Protein Isoforms; D001216:Asparagine; D006493:Heparin; D007770:L-Lactate Dehydrogenase; D003402:Creatine Kinase; D010741:Phospholipases A; D008239:Lysine